Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
45 drugs in development
By Therapeutic Area
top 6
R&D Momentum
100/100
Pipeline Velocity
95/100
Trial Completion Rate
73/100
Pipeline Concentration
19/100
Pipeline Freshness
58/100
Strategic Signals
Activity
Last 14 days
A Randomized Controlled Trial of Buspirone for Anxiety in Autistic Youth
A Phase 2 Study of Elranatamab in Combination With Isatuximab (ELISA) in Relapsed and Refractory Multiple Myeloma
Does Prophylactic Local Tobramycin Injection Lower Open Fracture Infection Rates?
Evaluation of Varenicline and Accelerated TMS for Reduction of Nicotine Use
Pilot Feasibility Trial of a Nurse-Led, Coping and Supportive Intervention (RESTORE) for Patients With Triple-Negative Breast Cancer
Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib to Prevent Gluten-induced Celiac Enteropathy and Symptoms in Celiac Disease Patients in Remission
Partners Calciphylaxis Biobank and Patient Registry
A Phase II Trial of Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Patients With Unresectable or Metastatic Melanoma
Exploring the Utility of a Novel BRAF Test in Patients With Melanoma
Sedation During Endoscopy Using Remimazolam: Efficacy in a Novel Exploration (SERENE)
Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep (MINDDS II)
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)